MDxHealth’s Prostate ConfirmMDx test has been found to help urologists to distinguish between true negative biopsies and occult prostate cancers undetected by biopsy and histopathological review.

The assay identifies epigenetic changes in prostate cancer-related genes to indicate the likely presence of cancer.

The prospective study evaluated 86 men with an initial histologically negative prostate biopsy and found the relative negative predictive value to be 96%.

The company is currently conducting a validation trial using the assay.

MDxHealth CEO Jan Groen said that additional clinical validation studies for an improved version of the assay under way, and the company looked forward to launching the test for urologists through commercial its CLIA laboratory in the first half of 2012.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.